NAD+

Longevity Research compound (not approved for human use)

Coenzyme (dinucleotide) · also known as Nicotinamide adenine dinucleotide, NAD

For reference only — not medical advice. Figures are commonly reported values compiled from published sources and may be wrong or out of date. Many compounds listed are not approved for human use. Talk to a licensed clinician before using any compound.

NAD+ takes part in hundreds of redox reactions and is also consumed by sirtuins, PARPs, and CD38. Because its levels fall with age, it has become a headline target in aging research, mostly via precursor supplements. Direct NAD+ is also given by clinics as a slow intravenous infusion.

Commonly reported dosing (500 mg vial)

Reconstituted with 3 mL → 166.667 mg/mL.

Also sold in 1000 mg vials.

Phase	Dose	Volume	U-100 units
Starting	50 mg	0.3 mL	30
Standard	75 mg	0.45 mL	45
Higher	100 mg	0.6 mL	60

Frequency: Once daily (community-reported), subcutaneous · Half-life: Not well characterized for subcutaneous use

Open in calculator

Commonly reported reconstitution steps

Vials are usually brought to room temperature (about 15-20 minutes) first.
3 mL of bacteriostatic water is added slowly down the inside wall of the 500 mg vial.
The vial is swirled gently until clear, not shaken.
This gives 166.67 mg/mL. Mixed vials are typically labeled with the date and refrigerated.

Storage

Before mixing: Sealed vials are commonly stored refrigerated (2-8 °C) and protected from light.

After mixing: Reconstituted solution is commonly kept refrigerated (2-8 °C) and protected from light.

Commonly used within 28 days of mixing.

How it works

As a cofactor it carries electrons in energy metabolism and serves as a substrate for sirtuin deacylases and DNA-repair enzymes, linking cellular energy status to stress resistance and gene regulation.

Researched for

Studied through precursors such as nicotinamide riboside for effects on NAD+ levels in human blood.
Examined in small clinic-based reports of intravenous NAD+ infusion tolerability.
Investigated in animal aging, metabolic, and neurodegeneration models.

Notes

Published human work with direct NAD+ is mostly slow intravenous infusion at roughly 500-750 mg; no study establishes the subcutaneous schedule shown, which is community-reported.
Subcutaneous administration is often reported as uncomfortable at higher concentrations.
Not FDA-approved as a finished drug; available as a compounded preparation. Sterility and endotoxin quality of compounded injectables is a recognised concern.